SeekingAlpha · Sep 22, 2026
AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver
AN2 Therapeutics looks attractive with a risk-adjusted base-case valuation of approximately $12 per share. Read why I rate ANTX stock a Buy now.
AN
NASDAQ · ANTX
AN2 Therapeutics, Inc.
Healthcare · Biotechnology
$4.88
Down-$0.01 (-0.20%)
Updated Sep 27, 2026, 2:56 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 30.14M
- P/E ratio
- -0.98
- Dividend yield
- 0.00%
- 52-week range
- $1.00 – $7.19
- Volume
- 155.13K
- Avg. volume
- 90.8K
Price performance
ANTX price history
1M range · 19 trading sessions · Daily adjusted prices
ANTX closed at $4.88 after 19 trading sessions, down 12.07% for the selected period.
- Last close
- $4.88
- Period change
- -12.07%
- Period low
- $4.83
- Period high
- $5.98
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $4.91 | $4.95 | $4.71 | $4.88 | 155.13K |
| Sep 24, 2026 | $4.77 | $5.06 | $4.72 | $4.89 | 258.94K |
| Sep 23, 2026 | $4.86 | $4.95 | $4.67 | $4.83 | 306.16K |
| Sep 22, 2026 | $5.00 | $5.05 | $4.70 | $4.83 | 191.68K |
| Sep 21, 2026 | $5.06 | $5.25 | $4.92 | $4.96 | 305.22K |
| Sep 18, 2026 | $4.89 | $5.15 | $4.80 | $5.05 | 670.95K |
| Sep 17, 2026 | $5.39 | $5.47 | $4.88 | $4.90 | 204.49K |
| Sep 16, 2026 | $5.38 | $5.44 | $5.295 | $5.34 | 146.05K |
| Sep 15, 2026 | $5.43 | $5.50 | $5.20 | $5.36 | 156.8K |
| Sep 14, 2026 | $5.43 | $5.645 | $5.34 | $5.46 | 221.49K |
| Sep 11, 2026 | $5.70 | $5.78 | $5.40 | $5.41 | 103.54K |
| Sep 10, 2026 | $5.56 | $5.88 | $5.54 | $5.69 | 222.31K |
| Sep 9, 2026 | $5.98 | $6.125 | $5.605 | $5.73 | 175.8K |
| Sep 8, 2026 | $6.00 | $6.06 | $5.76 | $5.98 | 335.29K |
| Sep 4, 2026 | $5.97 | $6.06 | $5.85 | $5.89 | 77.18K |
| Sep 3, 2026 | $6.05 | $6.20 | $5.79 | $5.95 | 199.66K |
| Sep 2, 2026 | $5.46 | $6.00 | $5.46 | $5.95 | 353.56K |
| Sep 1, 2026 | $5.53 | $5.67 | $5.40 | $5.48 | 215.42K |
| Aug 31, 2026 | $5.58 | $5.645 | $5.40 | $5.55 | 124.02K |
Latest ANTX news
The latest Smart Investors Daily articles mentioning ANTX.
Stock researchCompany · Overview
ANTX research
Overview
Company profile and research snapshot.
Company profile
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 20, 2026 | Guggenheim | Buy | — |
| May 14, 2026 | Leerink Partners | Outperform | — |
| May 5, 2025 | JMP Securities | Market Outperform | — |
| Mar 26, 2025 | Citizens Capital Markets | Market Outperform | — |
| Feb 25, 2025 | Citizens Capital Markets | Market Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 16, 2026
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
MENLO PARK, Calif., September 16, 2026--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor, M.D., the Company’s newly-appointed Chief Medical Officer.
Yahoo · Aug 31, 2026
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
MENLO PARK, Calif., August 31, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Onco
Benzinga · Aug 31, 2026
AN2 Therapeutics To Reveal Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera At The SOHO 2026 Annual Meeting
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
